Athanasios Galanopoulos

950 total citations
40 papers, 492 citations indexed

About

Athanasios Galanopoulos is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Athanasios Galanopoulos has authored 40 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 17 papers in Genetics and 10 papers in Immunology. Recurrent topics in Athanasios Galanopoulos's work include Acute Myeloid Leukemia Research (23 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Immune Cell Function and Interaction (6 papers). Athanasios Galanopoulos is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Immune Cell Function and Interaction (6 papers). Athanasios Galanopoulos collaborates with scholars based in Greece, United States and Australia. Athanasios Galanopoulos's co-authors include Stelios Zimeras, Paraskevi Roussou, Michael Kyriakidis, Theodoros Marinakis, Apostolos Karavidas, Ιoannis Kotsianidis, Argiris Symeonidis, Helen Α. Papadaki, Maria Pagoni and Γεώργιος Θεοδώρου and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Cancer Research.

In The Last Decade

Athanasios Galanopoulos

37 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Athanasios Galanopoulos Greece	10	211	163	159	115	108	40	492
Laure Farnault France	11	135 0.6×	165 1.0×	185 1.2×	119 1.0×	86 0.8×	38	549
Q.H. Le France	8	313 1.5×	202 1.2×	170 1.1×	59 0.5×	163 1.5×	16	613
Gerlinde Mitterbauer‐Hohendanner Austria	10	327 1.5×	99 0.6×	99 0.6×	88 0.8×	215 2.0×	20	530
Sophie Rigaudeau France	11	238 1.1×	114 0.7×	165 1.0×	125 1.1×	137 1.3×	22	558
Juliette Lambert France	10	305 1.4×	113 0.7×	182 1.1×	186 1.6×	78 0.7×	26	578
S. Osanto Netherlands	5	233 1.1×	76 0.5×	131 0.8×	225 2.0×	45 0.4×	8	535
Metter Ge United States	9	189 0.9×	97 0.6×	261 1.6×	93 0.8×	59 0.5×	13	538
Iuliana Vaxman Israel	13	147 0.7×	34 0.2×	150 0.9×	312 2.7×	80 0.7×	57	489
Christoph Tinchon Austria	10	107 0.5×	163 1.0×	256 1.6×	90 0.8×	45 0.4×	26	480
Nicholas J. DiBella United States	9	119 0.6×	30 0.2×	89 0.6×	61 0.5×	131 1.2×	20	313

Countries citing papers authored by Athanasios Galanopoulos

Since Specialization

Citations

This map shows the geographic impact of Athanasios Galanopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Athanasios Galanopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Athanasios Galanopoulos more than expected).

Fields of papers citing papers by Athanasios Galanopoulos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Athanasios Galanopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Athanasios Galanopoulos. The network helps show where Athanasios Galanopoulos may publish in the future.

Co-authorship network of co-authors of Athanasios Galanopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Athanasios Galanopoulos. A scholar is included among the top collaborators of Athanasios Galanopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Athanasios Galanopoulos. Athanasios Galanopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Solomou, Elena E., Antonis Kattamis, Argiris Symeonidis, et al.. (2023). Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ. Blood Advances. 8(2). 399–402. 2 indexed citations

Diamantopoulos, Panagiotis, Athanasios Galanopoulos, Vassiliki Pappa, et al.. (2022). Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection. Annals of Hematology. 101(12). 2711–2717. 4 indexed citations

Diamantopoulos, Panagiotis, Athanasios Galanopoulos, Vasiliki Pappa, et al.. (2022). Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study. Therapeutic Advances in Hematology. 13. 1554007910–1554007910. 7 indexed citations

Lamprianidou, Eleftheria, Anastasiya Kazachenka, Elsa Bernard, et al.. (2021). Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine. Blood Advances. 5(1). 129–142. 7 indexed citations

Liapis, Konstantinos, Vasileios Papadopoulos, Alexandra Kourakli, et al.. (2020). Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study. SHILAP Revista de lepidopterología. 1(1). 255–261. 2 indexed citations

Diamantopoulos, Panagiotis, Argiris Symeonidis, Ιoannis Kotsianidis, et al.. (2019). Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. Annals of Hematology. 98(6). 1383–1392. 9 indexed citations

Papageorgiou, Sotirios G., Diamantina Vasilatou, Christos K. Kontos, et al.. (2018). The prognostic value of monosomal karyotype (MK) in higher‐risk patients with myelodysplastic syndromes treated with 5‐Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. American Journal of Hematology. 93(7). 895–901. 9 indexed citations

Papageorgiou, Sotirios G., Christos K. Kontos, Ιoannis Kotsianidis, et al.. (2018). The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematological Oncology. 36(4). 693–700. 7 indexed citations

Batsali, Aristea, Elisavet Kouvidi, Athanasios Galanopoulos, et al.. (2017). The Effect of 5-Azacitidine Treatment on the Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes. Blood. 130. 4242–4242. 1 indexed citations

10.

Papageorgiou, Sotirios G., Christos K. Kontos, Argiris Symeonidis, et al.. (2017). The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine. Blood. 130. 4252–4252. 1 indexed citations

11.

Diamantopoulos, Panagiotis, Theodoros P. Vassilakopoulos, Ιoannis Kotsianidis, et al.. (2017). Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. Blood Cancer Journal. 7(2). e533–e533. 12 indexed citations

12.

Pappa, Vasiliki, Αchilles Anagnostopoulos, Evangelos Briasoulis, et al.. (2016). A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. International Journal of Hematology. 105(2). 184–195. 2 indexed citations

13.

Lamprianidou, Eleftheria, Theodoros P. Vassilakopoulos, Sotirios G. Papageorgiou, et al.. (2015). The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. Clinical Cancer Research. 22(8). 1958–1968. 16 indexed citations

14.

Pontikoglou, Charalampos, Aristea Batsali, Athina Damianaki, et al.. (2014). Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway. Stem Cells and Development. 23(14). 1568–1581. 44 indexed citations

15.

Lamprianidou, Eleftheria, T. P. Vassilakopoulos, Sotirios G. Papageorgiou, et al.. (2014). Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer Journal. 4(2). e187–e187. 13 indexed citations

16.

Papanastasiou, Labrini, et al.. (2012). Case Report: Primary pituitary non-Hodgkin’s lymphoma developed following surgery and radiation of a pituitary macroadenoma. HORMONES. 11(4). 488–494. 10 indexed citations

17.

Spyropoulou‐Vlachou, Maria, Nikolaos J. Tsagarakis, Athanasios Galanopoulos, et al.. (2011). High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup. Human Immunology. 73(3). 278–281. 3 indexed citations

18.

Roussou, Paraskevi, Apostolos Karavidas, Theodoros Marinakis, et al.. (2010). Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up. American Journal of Hematology. 85(11). 894–896. 169 indexed citations

19.

Giannakoulas, Nikolaos, Μαρίνα Καρακάντζα, Γεώργιος Θεοδώρου, et al.. (2003). Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. British Journal of Haematology. 124(1). 97–105. 58 indexed citations

20.

Tsimberidou, Apostolia M., George Paterakis, George Androutsos, et al.. (2002). Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leukemia Research. 26(2). 143–154. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact